SeaStar Medical reports 5,997,246 shares outstanding; updates on clinical and commercial progress

SeaStar Medical Holding Corp

As of Dec 31, 2024, common shares outstanding: 5,997,246 (Jan 8, 2025: 5,977,246).
QUELIMMUNE (SCD-PED) FDA-approved Feb 2024; first commercial shipment July 2024; 4 hospital customers as of Q1 2025.
NEUTRALIZE-AKI adult pivotal trial 37% enrolled (74 of 200 subjects); 14 of 30 sites activated; CMS covers trial costs.
Four FDA Breakthrough Device Designations: adult AKI, cardiorenal syndrome w/ LVAD, hepatorenal syndrome, chronic dialysis.
Zero interest-bearing debt; cash use $11.3M YTD through Q3 2024; raised ~$20M new equity through Q3 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.